clinical trial · NCT05103254
Bempedoic Acid Pregnancy Surveillance Program
PregnancyHyperlipidemiasBempedoic AcidBempedoic Acid / Ezetimibe
brief summary
Bempedoic acid pregnancy surveillance program
started
Sep 1, 2021
primary completion
May 1, 2032
completion
May 1, 2032
last updated
May 17, 2024
detailed description
A surveillance study of females exposed to bempedoic acid or bempedoic acid/ezetimibe fixed combination drug product (FCDP) during pregnancy. Observational outcome data will be collected on pregnant females through pregnancy and infants through the first year of life.
official title
A Post-marketing, Long-term, Observational, Descriptive Study to Assess the Risk of Pregnancy and Maternal Complications and Adverse Effects on the Developing Fetus, Neonate, and Infant Among Women Exposed to Bempedoic Acid or Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) During Pregnancy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol